Article | December 26, 2018

Five Things To Know When it Comes To iRECIST

By Luke Gill

Laptop Work_450by300

Evaluation of patient response to treatment of solid tumors is undergoing an important evolution under the new iRECIST guidance issued in early 2017. The RECIST 1.1 guideline remains the gold standard, but iRECIST is focusing attention on the future of tumor assessment methods.

Here are five things you should know about iRECIST as the standard shapes up as an important tool in assessing solid tumors.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: